Skip to main content
HOUSE 2831117th CongressReferred to the Subcommittee on Health.

Prompt Approval of Safe Generic Drugs Act

Last Action
4/27/2021

Actions

  • 2021-04-27Referred to the Subcommittee on Health.
  • 2021-04-26Referred to the House Committee on Energy and Commerce.
  • 2021-04-26Introduced in House
  • 2021-04-26Introduced in House

CRS Summary

As of 2021-04-26 (00)

Prompt Approval of Safe Generic Drugs Act

This bill authorizes the Food and Drug Administration (FDA) to approve certain applications to market a drug even if the drug's labeling lacks certain safety information.

Specifically, an abbreviated application for approval of a generic drug shall not be ineligible for approval solely because the drug's labeling omits safety information that is protected under another drug's exclusivity protections. Similarly, a drug that is approved under this bill shall not be considered mislabeled for lacking such safety information.

Generally, an abbreviated application, for the purposes of this bill, is one that (1) uses required information from studies not conducted by the applicant; or (2) seeks approval of a drug that is, for drug approval purposes, a duplicate of an already-approved drug.

For any drug approved under this bill, the FDA shall require the drug's labeling to include any safety information that is necessary to assure safe use.

Subjects

  • Drug safety, medical device, and laboratory regulation
  • Marketing and advertising
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.